Mutations in the UL97 gene of cytomegalovirus (Herpesvirales: Herpesviridae: Cytomegalovirus: Human betaherpesvirus 5) associated with ganciclovir resistance in recipients of allogeneic hematopoietic stem cells

Cover Image

Cite item

Full Text

Abstract

Introduction. Infection caused by cytomegalovirus (CMV) is a serious problem for patients with weakened immunity, including patients with hematopoietic depression. The cases of complications associated with cytomegalovirus require antiviral therapy. However, during the natural mutation process, especially with prolonged use of drugs in suboptimal doses, CMV strains resistant to the action of antiviral drugs (such as ganciclovir, valganciclovir) may occur. Hypothetically, the emergence of resistance in the virus may cause a more aggressive course of infection, the ineffectiveness of antiviral therapy and, as a result, an increase in the number of deaths. In this regard, timely detection of mutations that can potentially lead to the resistance of the virus to antiviral drugs during hematopoietic stem cell transplantation (HSCT), as well as during organ and tissue transplantation, may be important when making a therapeutic decision. We describe three clinical cases for which the dynamics of the appearance of a mutant strain of CMV by the UL97 gene, which correlates with the viral load and clinical picture, is analyzed.

The aim of the study was to determine the timing of the occurrence of mutations in CMV phosphotransferase UL97 gene associated with resistance to antiviral drugs in patients with hemoblastoses after allogeneic hematopoietic stem cell (allo-HSCs) transplantation.

Material and methods. The study included 48 samples of CMV DNA isolated from the peripheral blood of three allo-HSCs recipients with CMV infection who were treated in the clinics of the FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia with oncohematological diseases during 2015–2017. Patients received conditional codes (PR, PD, and FS). Mutations associated with antiviral therapy (AVT) resistance were identified in all patients. Sanger sequencing was used for mutation detection. The obtained DNA sequences were analyzed using Nucleotide BLAST and Genome compiler software. Mutations were searched in MRA mutation resistance analyzer software. The nucleotide sequences were compared with the UL97 reference sequence of the Merlin CMV strain using this software environment.

Results and discussion. For all patients in whom the virus strains containing C592G (PR), C607F (PD) and C603W (FS) mutations were detected, the timing of the mutation occurrence was determined at days 187, 124 and 1184, respectively. The emergence of mutations with a high resistance factor was shown to be accompanied by an increase in viral load (VL), the appearance of a clinical picture characteristic of CMV infection and a lack of an adequate response to therapy with ganciclovir and its derivatives.

Conclusion. Using these results, it is proposed to develop the test system based on random polymerase chain reaction (rPCR) to detect mutations in the most frequently encountered codons: M460I/V, C592G, A591V, A594T/V, L595F/S, C603W. Given that the data on the prevalence of these mutations were obtained from foreign sources, it is advisable to conduct similar studies on the frequency of mutations in the UL97 gene among the population of the Russian Federation in order to improve the quality and accuracy of test systems.

About the authors

M. V. Demin

FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia

Author for correspondence.
Email: memindisha@gmail.com
ORCID iD: 0000-0002-7579-3442

Mikhail V. Demin, Biologist, Researcher of the Virological Safety Laboratory

125167, Moscow

Russian Federation

D. S. Tikhomirov

FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia

ORCID iD: 0000-0002-2553-6579

125167, Moscow

Russian Federation

B. V. Biderman

FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia

ORCID iD: 0000-0002-6253-3334

125167, Moscow

Russian Federation

M. Yu. Drokov

FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia

ORCID iD: 0000-0001-9431-8316

125167, Moscow

Russian Federation

A. B. Sudarikov

FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia

ORCID iD: 0000-0001-9463-9187

125167, Moscow

Russian Federation

T. A. Tupoleva

FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia

ORCID iD: 0000-0003-4668-9379

125167, Moscow

Russian Federation

F. P. Filatov

FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»; FSBI «National Research Centre for Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia

ORCID iD: 0000-0002-2385-9251

105064, Moscow; 123098, Moscow

Russian Federation

References

  1. Gerna G., Zavattoni M., Baldanti F., Furione M., Chezzi L., Revello M.G., et al. Circulating cFytomegalic endothelial cells are associated with high human cytomegalovirus (HCMV) load in AIDS patients with late-stage disseminated HCMV disease. J. Med. Virol. 1998; 55(1): 64–74.
  2. Göhring K., Hamprecht K., Jahn G. Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients. Comput. Struct. Biotechnol. J. 2015; 13: 153–9. https://doi.org/10.1016/j.csbj.2015.01.003
  3. Piret J., Boivin G. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Res. 2019; 163: 91–105. https://doi.org/10.1016/j.antiviral.2019.01.011
  4. Schaeffer H.J., Beauchamp L., de Miranda P., Elion G.B., Bauer D.J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978; 272(5654): 583–5. https://doi.org/10.1038/272583a0
  5. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008; 18(4): 233–46. https://doi.org/10.1002/rmv.574
  6. Göhring K., Wolf D., Bethge W., Mikeler E., Faul C., Vogel W., et al. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation. J. Clin. Virol. 2013; 57(1): 43–9. https://doi.org/10.1016/j.jcv.2013.01.003
  7. Britt W. Cytomegalovirus. In: Remington J.S., ed. Infectious Diseases of the Fetus and Newborn Infant. Elsevier; 2011: 706–55.
  8. Komatsu T.E., Pikis A., Naeger L.K., Harrington P.R. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathways. Antiviral Res. 2014; 101: 12–25. https://doi.org/10.1016/j.antiviral.2013.10.011
  9. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006; 71(2–3): 154–63. https://doi.org/10.1016/j.antiviral.2006.05.002
  10. Fischer L., Imrich E., Sampaio K.L., Hofmann J., Jahn G., Hamprecht K., et al. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. Antiviral Res. 2016; 131: 1–8. https://doi.org/10.1016/j.antiviral.2016.04.002
  11. Volfova P., Lengerova M., Lochmanova J., Dvorakova D., Ricna D., Palackova M., et al. Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR. J. Clin. Virol. 2014; 61(2): 270–4. https://doi.org/10.1016/j.jcv.2014.07.008
  12. Eckle T., Jahn G., Hamprecht K. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. J. Clin. Virol. 2004; 30(1): 50–6. https://doi.org/10.1016/j.jcv.2003.08.010
  13. Göhring K., Feuchtinger T., Mikeler E., Lang P., Jahn G., Handgretinger R., et al. Dynamics of the emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a pediatric stem-cell transplant recipient. J. Mol. Diagnostics. 2009; 11(4): 364–8. https://doi.org/10.2353/jmoldx.2009.080153
  14. Demin M.V., Biderman B.V., Glinshchikova O.A., Sudarikov A.B., Filatov F.P., Tikhomirov D.S., et al. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir resistance in recipients of allogeneic hematopoietic stem cell transplants. Clin. Microbiol. Antimicrob. Chemother. 2019; 21(4): 352–7. https://doi.org/10.36488/cmac.2019.4.352-357
  15. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 2002; 185(2): 162–9. https://doi.org/10.1086/338362

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022 Demin M.V., Tikhomirov D.S., Biderman B.V., Drokov M.Y., Sudarikov A.B., Tupoleva T.A., Filatov F.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).